$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Public Health

Judge Approves Bayer Roundup Settlement Worth 7.25 Billion

The Missouri settlement pays current and future lymphoma claims between $10,000 and $165,000 over up to 21 years. It resolves the lawsuits without resolving what the science says about glyphosate.

TML Health DeskNov 22, 5:54 AM ET · 2 min read
A boom sprayer at work in a field. The settlement pays its largest awards to people whose jobs exposed them to glyphosate daily. Photo: Chafer Machinery / CC BY 2.0, via Wikimedia Commons.
Summary

The claims get a grid. The science keeps its disagreement.

Tap a passage. React to the part that matters.

A Missouri judge gave final approval Friday to Bayer's $7.25 billion Roundup settlement, and the science question stays open.

Monsanto will pay into a claims fund in declining annual installments for up to 21 years, capped at $7.25 billion including money already paid. The program covers people exposed to Roundup or other glyphosate products before February 17, 2026 who developed non-Hodgkin lymphoma, and it also covers people who haven't been diagnosed yet but develop the disease later.

Individual payments run from $10,000 to $165,000, scaled by how much exposure a person's work involved, their age at diagnosis and the severity of the illness. Farm and grounds workers with daily exposure sit at the top of that scale. Judge Timothy Boyer called the average payouts fair and adequate in his written judgment, and $600 million of the total goes to attorneys' fees.

The settlement doesn't decide whether glyphosate causes cancer, and the agencies still don't agree with each other. The International Agency for Research on Cancer classified glyphosate as probably carcinogenic to humans in 2015, drawing on animal studies and mechanistic evidence. The U.S. Environmental Protection Agency has repeatedly concluded that it isn't likely to cause cancer at real-world exposure levels. A claims grid prices that disagreement by exposure and diagnosis; it doesn't settle the underlying question.

The approval lands five months after the Supreme Court ruled for Bayer in the Durnell case, throwing out a $1.25 million Missouri verdict and holding that federal labeling law shields the company from state failure-to-warn suits. Bayer's statement calls the court ruling and the settlement mutually reinforcing parts of one strategy, and Chief Executive Bill Anderson called the approval a decisive milestone in containing the litigation.

The order can still be appealed, and the claims program hasn't opened yet. For the people the grid covers, the open questions are now administrative ones: proving exposure dates, diagnosis dates and work history to a fund that will still be paying claims into the 2040s.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.